JPH0262880A - Dithiodiketopiperazine compound - Google Patents

Dithiodiketopiperazine compound

Info

Publication number
JPH0262880A
JPH0262880A JP63214135A JP21413588A JPH0262880A JP H0262880 A JPH0262880 A JP H0262880A JP 63214135 A JP63214135 A JP 63214135A JP 21413588 A JP21413588 A JP 21413588A JP H0262880 A JPH0262880 A JP H0262880A
Authority
JP
Japan
Prior art keywords
strain
formula
compound
chloroform
schulzeri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP63214135A
Other languages
Japanese (ja)
Inventor
Akira Kawashima
朗 川嶋
Yuko Yoshimura
吉村 祐子
Taku Mizutani
卓 水谷
Kazunori Hanada
和紀 花田
Sadafumi Omura
大村 貞文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority to JP63214135A priority Critical patent/JPH0262880A/en
Publication of JPH0262880A publication Critical patent/JPH0262880A/en
Pending legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

NEW MATERIAL:A compound, expressed by the formula and having the follow ing physico-chemical properties. Melting point; 89-92 deg.C. Elementary analysis (%) (as C31H38O9N2S2); C, 57.67; H, 5.80; N, 4.50; S, 9.85. Molecular weight; field desorption mass spectrometry (FD-MS), m/z 647(M+H). Molecular formula; C31H38O9N2S2. Optical rotation; [alpha] =-179.6 (C=0.044, CHCl3). Solubility; insoluble in water and soluble in methanol, ethanol, ethyl acetate, benzene and chloroform. Color reaction; negative to ninhydrine and ferric chloride reac tion and positive to iodine reaction and sulfuric acid. Neutral. Light-yellow powder, etc. USE:A blood platelet agglutination inhibitor. PREPARATION:A strain of Ramichlovidium Schulzeri var. Schulzeri F-2440 (FERM P-10187) is cultured at 25-28 deg.C and pH6.8-7 for 5 days.

Description

【発明の詳細な説明】 [産業上の利用分野] 本発明は血小板凝集抑制剤として有用なジチオジケトピ
ペラジン化合物に関する。
DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to dithiodiketopiperazine compounds useful as platelet aggregation inhibitors.

[従来の技術] 本発明のジチオジケトピペラジン化合物に類似の化合物
としてはスボリデスミンA (Sporidesmin
A)[テトラヘドロン レターズ(Tetrahedr
onLetters ) 、第3131頁、 (196
6年)コ、アラノチン(Aranotin ) [テト
ラヘドロンレターズ(Ietra−hedron Le
tters ) 、第4467頁、 (1968年)]
が知られている。
[Prior Art] A compound similar to the dithiodiketopiperazine compound of the present invention is Sporidesmin A (Sporidesmin A).
A) [Tetrahedron Letters
onLetters), page 3131, (196
6th year) Ko, Aranotin [Tetrahedron Letters (Ietra-hedron Le
tters), p. 4467, (1968)]
It has been known.

[発明が解決しようとする問題点] 本発明の目的は、血小板凝集に対して抑制作用を有する
新規な化合物を提供することにある。
[Problems to be Solved by the Invention] An object of the present invention is to provide a novel compound that has an inhibitory effect on platelet aggregation.

[問題点を解決するための手段] 本発明者らは、新規な生理活性物質の探索を目的として
多数の菌株を土壌より分離し、その菌株の培養物につい
て種々検討した結果、ある種の菌株が血小板凝集に対す
る強い抑制作用を有する新蜆な物質を生産することを見
出し本発明を完成した。
[Means for Solving the Problems] The present inventors isolated a large number of bacterial strains from soil for the purpose of searching for new physiologically active substances, and as a result of conducting various studies on the cultures of the strains, certain strains of bacteria were discovered. The present invention has been completed by discovering that a new substance can be produced that has a strong inhibitory effect on platelet aggregation.

すなわち、本発明は、下記式! 及び下記式■で示され
るジチオジケトピペラジン化合物(以下式■の化合物を
PI−061,式■の化合物をPI−063と称する。
That is, the present invention is based on the following formula! and a dithiodiketopiperazine compound represented by the following formula (1) (hereinafter, the compound of formula (1) is referred to as PI-061, and the compound of formula (2) is referred to as PI-063.

)である。).

本発明の目的物質を生産する菌株は、本発明者らが愛知
県東海市加木屋町の土壌より新たに分離した菌株であり
、微生物の名称「ラミクロリゾイウム シュルツアー 
バーシュルツアー F−2440(Ramichlor
idium 5chulzeri var。
The strain that produces the target substance of the present invention is a strain newly isolated by the present inventors from the soil of Kagiya-cho, Tokai City, Aichi Prefecture, and the microorganism name is "Lamicrhizoium schultzer".
Birschltour F-2440 (Ramichlor
idium 5chulzeri var.

’5chulzeri F −2440) J及び微生
物寄託番号「微工研菌寄第10187号(FERM P
−10187) Jとして工業技術院微生物工業技術研
究所に寄託されている。この菌株を培養し、本発明の目
的物質を得ることができる。
'5chulzeri F-2440) J and Microorganism Deposit No. 10187 (FERM P
-10187) has been deposited with the Institute of Microbial Technology, Agency of Industrial Science and Technology as J. This strain can be cultured to obtain the target substance of the present invention.

この菌株の菌学的性状を以下に示す。The mycological properties of this strain are shown below.

1)形態 本菌株は、オートミル寒天培地やYpSs寒天培地など
で良好に成育するが、分生子の着生は中程度である。オ
ートミル寒天培地上に成育したコロニーを顕微鏡下で観
察すると、菌糸は透明で隔壁を有し、高度に分枝してい
る分生子柄は主に培地中あるいは培地表面の基底菌糸か
ら垂直又はやや屈曲に生じ(30〜150X2.2〜3
.8μ)、その先端部に多数の小歯状突起を形成する1
分生子は単細胞で小歯上よりシンボジオ型に形成される
。電子顕微鏡で観察すると分生子は波型で、大きさは5
.2〜9.5X 2.0〜3.2μであり、その表面は
滑面を呈していた。
1) Morphology This strain grows well on oatmeal agar medium, YpSs agar medium, etc., but conidial settlement is moderate. When a colony grown on an oatmilk agar medium is observed under a microscope, the hyphae are transparent and have septa, and the highly branched conidiophores are mainly perpendicular or slightly bent from the basal hyphae in the medium or on the surface of the medium. (30-150X2.2-3
.. 8μ), forming many small teeth at its tip 1
The conidia are single cells and are formed in a symbogeotype on the denticles. When observed with an electron microscope, the conidia are wave-shaped and the size is 5.
.. 2-9.5X 2.0-3.2μ, and its surface was smooth.

2)培地上の諸性状 各種培地上で25℃で14日間培養したときの肉眼的観
察結果を第1表に示す。
2) Properties on media Table 1 shows the results of macroscopic observation when cultured on various media at 25°C for 14 days.

(以下、余白) 3)生理的、生態的性状 ■最適成育条件 本菌株の最適成育条件は、YpSs培地においてPH5
,1〜7.6、温度15〜25℃である。
(Hereinafter, blank space) 3) Physiological and ecological properties ■Optimal growth conditions The optimal growth conditions for this strain are YpSs medium with a pH of 5.
, 1 to 7.6, and the temperature is 15 to 25°C.

■成育の範囲 本菌株の成育の範囲はYpSs培地においてPH2,7
〜9.2、温度12〜30℃である。
■Growth range The growth range of this strain is PH2, 7 in YpSs medium.
-9.2, temperature 12-30°C.

■好気性、嫌気性の区別;  好気性 以上の形態的特徴及び培養上の性状から本菌株うミクロ
リゾイウム属に属する可能性が示唆された。そこで前記
諸性状を基に宇田用俊−1椿啓介編1菌類図鑑、 (1
987年)及びG、S、de Hoog著のThe b
lack yeasts and allied Hy
phomycetes 5t−udies Mycol
l、15 77 (1977)に報告されている多くの
既知菌株と比較検討した結果、本菌株はRan+ich
loridium 5chulzeri var、5c
hulzeriに最も近い性状を示していた。
■Distinction between aerobic and anaerobic; From the morphological characteristics that are more than aerobic and the culture characteristics, it was suggested that this strain may belong to the genus Microrhizoium. Therefore, based on the above-mentioned properties, Illustrated encyclopedia of fungi, Yotoshi Uda-1 edited by Keisuke Tsubaki, (1
987) and The b by G. S. de Hoog.
Lack yeasts and allied Hy
homycetes 5t-udies Mycol
As a result of comparison with many known bacterial strains reported in 1977, this strain was found to be Ran+ich.
loridium 5chulzeri var, 5c
It showed properties closest to those of Hulzeri.

以上の結果より本菌株はラミクロリディウムシュルツァ
ー バー シュルツァ−F−2440(Ram1chl
oridiuco 5chulzari var、5c
hulzeriF−2240)と命名した。
Based on the above results, this strain was identified as Ramirolidium Schulzer F-2440 (Ram1chl
oridiuco 5chulzari var, 5c
hulzeriF-2240).

本発明のPI−061及びPI−063の生産は、大略
一般の発酵生産物を生産する場合に準じ、各種の栄養物
質を含む培地で本菌株を好気的条件下で培養することに
より行なう。
The production of PI-061 and PI-063 of the present invention is carried out by culturing the present strain under aerobic conditions in a medium containing various nutritional substances, roughly in the same manner as in the production of general fermentation products.

培地は主として液体培地を用い、炭素源としてはグルコ
ース、シュクロース、糖蜜、スターチなどを単独又は混
合して用いる。窒素源としては肉エキス、酵母エキス、
大豆粉、ポリペプトンなどを単独または混合して用いる
A liquid medium is mainly used as the medium, and glucose, sucrose, molasses, starch, etc. are used alone or in combination as carbon sources. Nitrogen sources include meat extract, yeast extract,
Soy flour, polypeptone, etc. are used alone or in combination.

その他、本菌株の生育を助けPI−061及びPI−0
63の生産を促進する有機物及び無機塩を必要により添
加することができる。消泡剤としては、アデカノール、
シリコンなどを用いることができる。
In addition, PI-061 and PI-0 help the growth of this strain.
Organic substances and inorganic salts that promote the production of 63 can be added as necessary. As an antifoaming agent, Adekanol,
Silicon or the like can be used.

培養方法は振とう培養、通気撹拌培養などの好気培養が
適しており、PH4〜8.25〜30℃で2〜6日間、
望ましくはPH6,8〜7,0.25〜28℃で5日間
培養する。
As for the culture method, aerobic culture such as shaking culture and aerated agitation culture is suitable, and the pH is 4-8.25-30℃ for 2-6 days.
The culture is preferably carried out at pH 6, 8 to 7, and 0.25 to 28°C for 5 days.

この培養により生産されたPI−061及びPI−06
3を単離するには発酵生産物を採取する一般的な方法に
準じて行えばよい。
PI-061 and PI-06 produced by this culture
3 can be isolated according to a general method for collecting fermentation products.

PI−061及びPI−063は主に培養液中に蓄積さ
れるので、例えば、次の方法が効果的である。
Since PI-061 and PI-063 are mainly accumulated in the culture solution, the following method is effective, for example.

すなわち、培養終了後、遠心分離又は濾過により培養P
液と菌体を得、このP液は吸着樹脂、例えば、ダイヤイ
オンHP−20(商品名:三菱化成工業社製)に吸着さ
せた後、低級アルコール、アセトンなどの有機溶媒でP
I−061及びPI−063を溶出きせる。菌体はアセ
トンなどの有機溶媒で抽出する0次いでこの抽出液と吸
着樹脂からの溶出液を合して濃縮後、酢酸エチル、ベン
ゼン、クロロホルムなどの非水溶性有機溶媒に転溶し、
これを濃縮してシロップ状とする。このシロップを再度
酢酸エチル、ベンゼン、クロロホルムなどの有機溶媒に
溶解し、セファデックスLH−20(商品名:ファルマ
シア社製)を用いたゲル濾過及び高速液体クロマトグラ
フィーに付することにより、PI−061及びPI−0
63を精製、単離することができる。
That is, after the completion of culture, culture P is removed by centrifugation or filtration.
After obtaining a solution and bacterial cells, this P solution is adsorbed on an adsorption resin such as Diaion HP-20 (product name: manufactured by Mitsubishi Chemical Industries, Ltd.), and then P solution is absorbed with an organic solvent such as a lower alcohol or acetone.
I-061 and PI-063 are eluted. The bacterial cells are extracted with an organic solvent such as acetone.Then, this extract and the eluate from the adsorption resin are combined and concentrated, and then transferred to a water-insoluble organic solvent such as ethyl acetate, benzene, or chloroform.
Concentrate this to form a syrup. This syrup was dissolved again in an organic solvent such as ethyl acetate, benzene, or chloroform, and subjected to gel filtration using Sephadex LH-20 (trade name: manufactured by Pharmacia) and high performance liquid chromatography to obtain PI-061. and PI-0
63 can be purified and isolated.

以上の精製方法で単離されたPI−061及びPI−0
63は下記の理化学的性質を有している。
PI-061 and PI-0 isolated by the above purification method
63 has the following physical and chemical properties.

PI−061: (a)融点 89〜92℃ (b)元素分析値(、C31H3809N2S2として
)(理論値) C: 57.59%、H:5.88%、N:4.33%
S : 9.91% (実測値) C: 57.67%、H:5.80%、N、4.50%
S:9.85% (e)分子量 F D−MS : m/z 647(M+H)(d)分
子式 %式% (e)旋光度 [αコ”−−179,6° (C=0.044 、 c
HcI4)(f)紫外線吸収スペクトル メタノール中で測定した結果を第1図に示す。
PI-061: (a) Melting point 89-92°C (b) Elemental analysis value (as C31H3809N2S2) (theoretical value) C: 57.59%, H: 5.88%, N: 4.33%
S: 9.91% (actual value) C: 57.67%, H: 5.80%, N, 4.50%
S: 9.85% (e) Molecular weight F D-MS: m/z 647 (M+H) (d) Molecular formula % formula % (e) Optical rotation [α co”-179,6° (C=0.044 , c
HcI4) (f) Ultraviolet absorption spectrum The results of measurements in methanol are shown in FIG.

(g)’H−NMRスペクトル 重クロロホルム中400MHzで測定した結果を第2図
に示す。
(g)'H-NMR spectrum The results measured at 400 MHz in deuterated chloroform are shown in FIG.

(h)溶剤に対する溶解性 水に不溶。メタノール、エタノール、酢酸エチル、ベン
ゼン、クロロホルムに可溶。
(h) Solubility in solvents Insoluble in water. Soluble in methanol, ethanol, ethyl acetate, benzene, and chloroform.

(i)呈色反応 ニンヒドリン、塩化第二鉄反応:陰性 ヨード反応、硫酸      :陽性 (j)塩基性、酸性、中性の区別 中性 (k)物質の色と形状 淡黄色粉末 PI−063: (a)元素分析値(C29H3209N2S2として)
(理論値) C: 56.49%、 H: 5.19%、 N : 
4.56%S : 10.39% (実測値) C: 56.66%、 H: 5.32%、 N : 
4.62%S : 10.50% (b)分子量 FD−MS :m/z 617(M+H)”(d)分子
式 %式% (f)紫外線吸収スペクトル アセトニトリル中で測定した結果を第3図に示す。
(i) Color reaction Ninhydrin, ferric chloride reaction: Negative iodine reaction, Sulfuric acid: Positive (j) Basic, acidic, neutral (k) Color and shape of the substance Pale yellow powder PI-063: (a) Elemental analysis value (as C29H3209N2S2)
(Theoretical value) C: 56.49%, H: 5.19%, N:
4.56% S: 10.39% (actual value) C: 56.66%, H: 5.32%, N:
4.62%S: 10.50% (b) Molecular weight FD-MS: m/z 617 (M+H)" (d) Molecular formula % Formula % (f) Ultraviolet absorption spectrum The results measured in acetonitrile are shown in Figure 3. show.

(g)’H−NMRスペクトル 重クロロホルム中400MHzで測定した結果を第4図
に示す。
(g)'H-NMR spectrum The results measured at 400 MHz in deuterated chloroform are shown in FIG.

(h)溶剤に対する溶解性 水に不溶、メタノール、エタノール、酢酸エチル、ベン
ゼン、クロロホルムに可溶。
(h) Solubility in solvents Insoluble in water, soluble in methanol, ethanol, ethyl acetate, benzene, and chloroform.

(i)呈色反応 ニンヒドリン、塩化第二鉄反応:陰性 ヨード反応、硫酸      :陽性 <j)塩基性、酸性、中性の区別 中性 (k)物質の色と形状 淡黄色油状物質 [発明の効果] 本発明のPI−061及びPI−063は、アラキドン
酸、アデノシンニリン酸、フラーゲンによる血小板凝集
に対して優れた抑制作用を有する新規の生理活性物質で
あり、血栓症などの治療薬として有用である。
(i) Color reaction Ninhydrin, ferric chloride reaction: negative iodine reaction, sulfuric acid: positive Effects] PI-061 and PI-063 of the present invention are novel physiologically active substances that have an excellent inhibitory effect on platelet aggregation caused by arachidonic acid, adenosine diphosphoric acid, and flagen, and are useful as therapeutic agents for thrombosis, etc. It is.

[実施例] 次に、実施例及び試験例を挙げて本発明を具体的に説明
する。
[Example] Next, the present invention will be specifically described with reference to Examples and Test Examples.

(実施例) (1)内容量50R,のジャーファーメンタ−容器にグ
ルコース4%、ポリペプトン1%、酵母エキス0.1%
から成る培地30党を入れ滅菌した。これと同じ組成の
培地で30℃、4日間往復振とう培養した本菌株の菌液
を前記滅菌培地に1.6%植菌し、30℃、4日間撹拌
通気培養した。
(Example) (1) 4% glucose, 1% polypeptone, 0.1% yeast extract in a jar fermenter container with a content capacity of 50R.
A medium consisting of 30 parts was added and sterilized. The sterilized medium was inoculated with 1.6% of the bacterial solution of this strain, which had been cultured with reciprocating shaking at 30°C for 4 days in a medium having the same composition as this, and cultured with stirring and aeration at 30°C for 4 days.

培養経了後、培養液150R,を濾過し菌体とP液に分
け、菌体は20f!、のアセトンを加え抽出した。
After culturing, 150R of the culture solution was filtered and separated into bacterial cells and P solution, and the bacterial cells were 20f! , and extracted with acetone.

p液は吸着樹脂[ダイヤイオンHP−20(商品名;三
菱化成工業社製) 5000af ]に吸着させた後精
製水101で洗浄後、アセトン8党で活性物質を溶出し
た。菌体由来のアセトン抽出液とP液由来のアセトン溶
出液を合わせ、アセトンを留去後残渣を2f!、の酢酸
エチルで2回抽出した。酢酸エチル層を無水硫酸ナトリ
ウムで脱水後、濃縮乾固し、褐色の油状物質18gを得
た。
The p solution was adsorbed on an adsorption resin [Diaion HP-20 (trade name; manufactured by Mitsubishi Chemical Industries, Ltd.) 5000af], washed with purified water 101, and the active substance was eluted with 8 parts of acetone. Combine the acetone extract derived from the bacterial cells and the acetone eluate derived from the P solution, and after distilling off the acetone, the residue is 2f! , twice with ethyl acetate. The ethyl acetate layer was dehydrated with anhydrous sodium sulfate and then concentrated to dryness to obtain 18 g of a brown oily substance.

(2)得られた油状物質18gを1000!!のクロロ
ホルムに溶解し、クロロホルムで調製したシリカゲルカ
ラムクロマトグラフィー[ワフーゲルC−200(商品
名:和光紬薬工業(株)製)コの1flカラムに吸着さ
せた。クロロホルム2fLで洗浄後、クロロホルム−ア
セトン(80:20)で溶出を行ない、濃縮乾固するこ
とにより2gの褐色油状物質を得た。得られた試料をア
セトンで調製したセファデックスLH−20(商品名;
ファルマシア社製、500ae )にてゲル濾過を行い
PI−061及びPI−063を含む両分を集め濃縮乾
固し、1.2gの黄色粉末を得た。得られた1、2gの
粗粉末をトヨバールHW−40(商品名;東洋ソーダ類
、300d ’)下にてゲル濾過を行い淡黄色粉末とし
て40mgのPI−061と淡黄色油状物質として3m
gのPI−063を得た。
(2) 18g of the obtained oily substance for 1000! ! was dissolved in chloroform and adsorbed onto a 1 fl column of silica gel column chromatography [Wafugel C-200 (trade name: manufactured by Wako Tsumugi Kogyo Co., Ltd.) prepared with chloroform. After washing with 2 fL of chloroform, elution was performed with chloroform-acetone (80:20), and 2 g of a brown oily substance was obtained by concentrating and drying. Sephadex LH-20 (trade name;
Gel filtration was performed using 500ae (manufactured by Pharmacia), and both fractions containing PI-061 and PI-063 were collected and concentrated to dryness to obtain 1.2 g of yellow powder. 1 to 2 g of the obtained crude powder was gel-filtered under Toyovar HW-40 (trade name: Toyo Soda Rui, 300d') to obtain 40 mg of PI-061 as a pale yellow powder and 3 m of PI-061 as a pale yellow oil.
g of PI-063 was obtained.

(試験例) 血小板凝集阻害作用 (1)血小板の調製法 体重2.0〜2.5kgの雄家兎の総頚動脈より採血し
、血液量の10分の1容の3.8%クエン酸ナトリウム
溶液を加えて軽く混和し、1300Xgで2分間遠心分
離した上清を多血小板血漿(以下、’PRP、という)
とした。沈澱を更に1600Xgで10分間遠心分離し
て得られた上清を乏血小板血漿(以下、 rP P P
、という)とした。
(Test example) Platelet aggregation inhibitory effect (1) Preparation method of platelets Collect blood from the common carotid artery of a male rabbit weighing 2.0 to 2.5 kg, and add 3.8% sodium citrate to 1/10th the blood volume. Add the solution, mix gently, and centrifuge at 1300Xg for 2 minutes.
And so. The precipitate was further centrifuged at 1600Xg for 10 minutes, and the resulting supernatant was collected as platelet-poor plasma (rP P P
).

(2)凝集惹起剤の調製法 あらかじめアラキドン酸(シグマ社製)はエタノールで
、アデノシンニリン酸又はコラーゲン(京都第一化学社
製、アグリバック)は生理食塩水で所要濃度に希釈し、
前記成分を個別に含む凝集惹起剤を調製した。
(2) Preparation method of aggregation inducing agent Arachidonic acid (manufactured by Sigma) is diluted with ethanol and adenosine diphosphoric acid or collagen (manufactured by Kyoto Daiichi Kagaku Co., Ltd., Agrivac) is diluted with physiological saline to the required concentration.
An aggregation inducing agent containing each of the above components was prepared.

(3)血小板凝集阻害活性測定法 200Pf1のPRPを採り、PPPとの吸光度の差を
一定にした後、メタノールにて所要濃度に調製したPI
−061及びPI−063をPRPに加え、撹拌した。
(3) Platelet aggregation inhibitory activity measurement method 200Pf1 PRP was taken, and after making the difference in absorbance with PPP constant, PI was adjusted to the required concentration with methanol.
-061 and PI-063 were added to PRP and stirred.

対照はメタノールのみを使用した。次いで、上記凝集惹
起剤(最終濃度:アラキドン酸の場合0.1mM、アデ
ノシンニリン酸の場合10μM、コラーゲンの場合10
に/d)を添加し、吸光度の変化を二元バイオサイエン
ス社プレイドレット アグリゲーション トレーサー 
4A型血小板凝集計を用い、ボーン等の比濁法[Bor
n、 J、 Physiol、 、第168巻第178
ページ(1968年)]により測定し、PI−061及
びPI−063の50%血小板凝集阻害濃度(tC,、
値)を求めた。
As a control, only methanol was used. Next, the above aggregation-inducing agent (final concentration: 0.1 mM for arachidonic acid, 10 μM for adenosine diphosphate, 10 μM for collagen)
Add /d) and measure the change in absorbance using Binary Bioscience Plaidlet Aggregation Tracer.
Using a type 4A platelet aggregometer, the nephelometric method of Born et al.
n, J, Physiol, vol. 168, no. 178
Page (1968)], and the 50% platelet aggregation inhibitory concentration (tC,
value) was calculated.

その結果を第2表に示した。The results are shown in Table 2.

MHzで測定したPI−063の’H−NMRスペクト
ルを示す。
The 'H-NMR spectrum of PI-063 measured at MHz is shown.

第  2  表Table 2

Claims (2)

【特許請求の範囲】[Claims] (1)式 ▲数式、化学式、表等があります▼ で表されるジチオジケトピペラジン化合物。(1) Formula ▲Contains mathematical formulas, chemical formulas, tables, etc.▼ A dithiodiketopiperazine compound represented by (2)式 ▲数式、化学式、表等があります▼ で表されるジチオジケトピペラジン化合物。(2) Formula ▲Contains mathematical formulas, chemical formulas, tables, etc.▼ A dithiodiketopiperazine compound represented by
JP63214135A 1988-08-29 1988-08-29 Dithiodiketopiperazine compound Pending JPH0262880A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP63214135A JPH0262880A (en) 1988-08-29 1988-08-29 Dithiodiketopiperazine compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63214135A JPH0262880A (en) 1988-08-29 1988-08-29 Dithiodiketopiperazine compound

Publications (1)

Publication Number Publication Date
JPH0262880A true JPH0262880A (en) 1990-03-02

Family

ID=16650809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63214135A Pending JPH0262880A (en) 1988-08-29 1988-08-29 Dithiodiketopiperazine compound

Country Status (1)

Country Link
JP (1) JPH0262880A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111205308A (en) * 2020-01-19 2020-05-29 中国科学院海洋研究所 A kind of thiodiketopiperazine compound and its preparation method and application

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111205308A (en) * 2020-01-19 2020-05-29 中国科学院海洋研究所 A kind of thiodiketopiperazine compound and its preparation method and application
CN111205308B (en) * 2020-01-19 2022-03-15 中国科学院海洋研究所 Sulfo-diketone piperazine compound and preparation method and application thereof

Similar Documents

Publication Publication Date Title
US3956337A (en) Process for the preparation of D-gluconic-δ-lactam
JPH0262880A (en) Dithiodiketopiperazine compound
JPS625990A (en) Antibiotic substance and production thereof
JPH03227971A (en) Carbazole compound
JPH0725878A (en) Platelet aggregation inhibitor PI-334
JP3641013B2 (en) Novel cell adhesion inhibitors Macrospheride A and B and process for producing them
JPH01193284A (en) Physiologically active substance pi-08s
JPS6112291A (en) Physiologically active substance pi-885
JPS6034556B2 (en) Antibiotic C-15003
JPS59179092A (en) 3(2-substituted-oxazol-5-yl)indole, its salt and their preparation
JPS61130250A (en) Antibiotic caf-0603
JPH03227991A (en) Dithiodiketopiperazine compound
JPH04128296A (en) Physiologically active substance pi-200,201
JPH04159274A (en) Benzoquinone compound
JPH0341089A (en) Physiologically active substance 3127
JPH01124392A (en) Physiologically active substance pi3430
JPH0632778A (en) Carbazole compound
JPH0262859A (en) Gamma-lactam compound
JPS5924995B2 (en) New antibiotic Nanaomycin E and its production method
JPS58175490A (en) Physiologically active substance ss 12538 a, its preparation and novel bacterium producing it
JPH06228144A (en) Benzaldehyde compound
JPH0310689A (en) Physiologically active substance fd-839
JPH04117346A (en) Phospholipase a2 inhibiting substance
JPS62175494A (en) Physiologically active substance fed-885
BE633630A (en)